ストックスクリーナーアプリを入手
146.63
1.88%
2.70
アフターアワーズ：
146.52
-0.11
-0.08%
前日終値:
$143.93
開ける：
$143.5
24時間の取引高:
5.21M
Relative Volume:
0.72
時価総額：
$182.03B
収益：
$29.45B
当期純損益:
$8.51B
株価収益率:
21.62
EPS:
6.7823
ネットキャッシュフロー:
$9.46B
1週間 パフォーマンス:
-2.27%
1か月 パフォーマンス:
-3.33%
6か月 パフォーマンス:
+26.67%
1年 パフォーマンス:
+24.89%
1日の値動き範囲:
$143.49
$146.92
1週間の範囲:
$142.77
$148.92
52週間の値動き範囲:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, NVS, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
146.63 | 178.68B | 29.45B | 8.51B | 9.46B | 6.7823 |
|
LLY
Lilly Eli Co
|
1,008.39 | 884.36B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.59 | 579.34B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
227.45 | 406.87B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
162.79 | 305.53B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.95 | 301.19B | 58.80B | 10.24B | 8.98B | 3.2788 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know - Yahoo Finance Singapore
How Low Can Gilead Sciences Stock Really Go? - Trefis
Swiss National Bank Has $398 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Schroder Investment Management Group Has $230.08 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by WINTON GROUP Ltd - MarketBeat
Vinva Investment Management Ltd Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Kiltearn Partners LLP - MarketBeat
Natixis Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
B. Metzler seel. Sohn & Co. AG Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Citigroup Maintains Buy on GILD (Gilead Sciences, Inc.) March 2026 - Meyka
Arcellx set to report earnings amid $7.8B Gilead deal - Investing.com
United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Has $2.81 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Parallel Advisors LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Korea Investment CORP Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Rhenman & Partners Asset Management AB Sells 88,000 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Blair William & Co. IL - MarketBeat
Is It Time To Reassess Gilead Sciences (GILD) After Its Strong Share Price Run - Yahoo Finance
Gilead’s BIC LEN HIV Results Highlight Valuation Gap And Future Potential - Yahoo Finance
Gilead Sciences, Inc. $GILD Shares Purchased by HUB Investment Partners LLC - MarketBeat
Munich Reinsurance Co Stock Corp in Munich Takes $67.50 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
First Trust Advisors LP Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Is Gilead Sciences Inc. stock overvalued by current metricsWeekly Trade Review & Low Drawdown Momentum Trade Ideas - Naître et grandir
These 3 Cash Flow Machines Provide Stability in Uncertain Markets - Investing.com
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term - Yahoo Finance
BofA reiterates Gilead Sciences stock Buy rating on Yeztugo uptake - Investing.com
Gilead in talks with South Africa to start local production of new HIV therapy - Seeking Alpha
Gilead Sciences, Inc. $GILD Stock Position Lifted by Orion Porfolio Solutions LLC - MarketBeat
Kingsview Wealth Management LLC Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Edgar Lomax Co. VA Has $19.46 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Fisher Asset Management LLC - MarketBeat
South Africa seeks local production of Gilead’s HIV prevention drug - WHTC
Gilead and South Africa are negotiating a license for local production of new HIV drug - statnews.com
Stonebridge Capital Advisors LLC Sells 9,029 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - Yahoo Finance
South Dakota Investment Council Cuts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Picton Mahoney Asset Management Boosts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences stock forecast for 2030: Can $7.8B Arcellx deal push GILD to $220 with no patent cliff until 2036? - Traders Union
Crossmark Global Holdings Inc. Grows Stake in Gilead Sciences, Inc. $GILD - MarketBeat
South Africa seeks local production of Gilead's HIV prevention drug - marketscreener.com
Is Gilead Sciences, Inc. (GILD) a Good Investment at the Moment? - Bitget
Let me see you One2PrEP: Gilead campaign targets stigma with pop culture punch - Medical Marketing and Media
Griffith & Werner Inc. Makes New $1.77 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Dimensional Fund Advisors LP Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Multiple Myeloma Market 2026: Gilead Sciences Acquires Arcellx for $7.8B to Control CAR-T Therapy - openPR.com
Gilead Sciences, Inc. $GILD Shares Sold by CI Investments Inc. - MarketBeat
Gilead Sciences Stock To $192? - Trefis
How Does Gilead Sciences Stock Stack Up Against Its Peers? - Trefis
Gilead Sciences (GILD) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead Sciences’ Yeztugo Revenue Is Set to Jump 400%: Here’s What Comes Next - TIKR.com
Gilead at TD Cowen Conference: Strategic Growth and Expansion - Investing.com
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
3.11%
0.89%
大文字化:
|
ボリューム (24 時間):